WO2001046166A2 - Partially saturated calcium channel blockers - Google Patents
Partially saturated calcium channel blockers Download PDFInfo
- Publication number
- WO2001046166A2 WO2001046166A2 PCT/CA2000/001558 CA0001558W WO0146166A2 WO 2001046166 A2 WO2001046166 A2 WO 2001046166A2 CA 0001558 W CA0001558 W CA 0001558W WO 0146166 A2 WO0146166 A2 WO 0146166A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- rings
- aliphatic cyclic
- aromatic
- Prior art date
Links
- 0 C1*CCNC1 Chemical compound C1*CCNC1 0.000 description 5
- ZFEVFMAXGKGLMH-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(CCCCC(c1ccccc1)c1ccccc1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(CCCCC(c1ccccc1)c1ccccc1)=O)=O ZFEVFMAXGKGLMH-UHFFFAOYSA-N 0.000 description 1
- UXXLTPGCINZEFM-UHFFFAOYSA-N Fc1ccc(C(CCCCl)c(cc2)ccc2F)cc1 Chemical compound Fc1ccc(C(CCCCl)c(cc2)ccc2F)cc1 UXXLTPGCINZEFM-UHFFFAOYSA-N 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N O=C(C1CCCCC1)Cl Chemical compound O=C(C1CCCCC1)Cl RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- LVZYAILHUMFBPA-UHFFFAOYSA-N O=C(CCCCC(c1ccccc1)c1ccccc1)N(CC1)CCN1C(C1CCCCC1)=O Chemical compound O=C(CCCCC(c1ccccc1)c1ccccc1)N(CC1)CCN1C(C1CCCCC1)=O LVZYAILHUMFBPA-UHFFFAOYSA-N 0.000 description 1
- NNGBAXIORLTZGX-UHFFFAOYSA-N O=C(CCCCC(c1ccccc1)c1ccccc1)N(CC1)CCN1C(Cc1ccccc1)=O Chemical compound O=C(CCCCC(c1ccccc1)c1ccccc1)N(CC1)CCN1C(Cc1ccccc1)=O NNGBAXIORLTZGX-UHFFFAOYSA-N 0.000 description 1
- AWYGRPBJKCVXOE-UHFFFAOYSA-N OC(CCCCC(c1ccccc1)c1ccccc1)=O Chemical compound OC(CCCCC(c1ccccc1)c1ccccc1)=O AWYGRPBJKCVXOE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA02006137A MXPA02006137A (en) | 1999-12-20 | 2000-12-20 | Partially saturated calcium channel blockers. |
CA2397681A CA2397681C (en) | 1999-12-20 | 2000-12-20 | Partially saturated calcium channel blockers |
AU24957/01A AU784848B2 (en) | 1999-12-20 | 2000-12-20 | Partially saturated calcium channel blockers |
JP2001547077A JP2003518107A (en) | 1999-12-20 | 2000-12-20 | Partially saturated calcium channel blocker |
EP00988532A EP1242398A2 (en) | 1999-12-20 | 2000-12-20 | Partially saturated calcium channel blockers |
NO20022948A NO326939B1 (en) | 1999-12-20 | 2002-06-19 | Calcium channel blocking compounds and pharmaceutical composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17276599P | 1999-12-20 | 1999-12-20 | |
US60/172,765 | 1999-12-20 | ||
US47692999A | 1999-12-30 | 1999-12-30 | |
US09/476,929 | 1999-12-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001046166A2 true WO2001046166A2 (en) | 2001-06-28 |
WO2001046166A3 WO2001046166A3 (en) | 2002-03-07 |
Family
ID=26868438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2000/001558 WO2001046166A2 (en) | 1999-12-20 | 2000-12-20 | Partially saturated calcium channel blockers |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1242398A2 (en) |
JP (1) | JP2003518107A (en) |
AU (1) | AU784848B2 (en) |
CA (1) | CA2397681C (en) |
MX (1) | MXPA02006137A (en) |
NO (1) | NO326939B1 (en) |
WO (1) | WO2001046166A2 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7378420B2 (en) | 2004-08-30 | 2008-05-27 | Neuromed Pharmaceuticals Ltd. | Urea derivatives as calcium channel blockers |
US7511077B2 (en) | 2005-02-09 | 2009-03-31 | Neuromed Pharmaceuticals Ltd. | Diamine calcium channel blockers |
EP2061780A1 (en) * | 2006-09-14 | 2009-05-27 | Neuromed Pharmaceuticals, Ltd. | Diaryl piperidine compounds as calcium channel blockers |
US7589109B2 (en) | 2005-02-22 | 2009-09-15 | Pfizer Inc | Oxyindole derivatives |
US7595329B2 (en) | 2004-06-15 | 2009-09-29 | Pfizer Inc | Benzimidazolone carboxylic acid derivatives |
US7659286B2 (en) | 2006-10-20 | 2010-02-09 | Astrazeneca Ab | N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide |
US7723349B2 (en) | 2003-04-24 | 2010-05-25 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
WO2011148888A1 (en) | 2010-05-27 | 2011-12-01 | あすか製薬株式会社 | Heterocyclic ring compound and h1 receptor antagonist |
US9434692B2 (en) | 2006-10-03 | 2016-09-06 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
WO2016173817A1 (en) * | 2015-04-28 | 2016-11-03 | Unilever Plc | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US9801856B2 (en) | 2008-10-28 | 2017-10-31 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US10059691B2 (en) | 2008-04-02 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US10058549B2 (en) | 2007-08-15 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-α]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10307355B2 (en) | 2015-04-28 | 2019-06-04 | Conopco, Inc. | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5428038A (en) | 1991-04-11 | 1995-06-27 | Dr. Willmar Schwabe Gmbh & Co. | Benzopyranones, a method for producing them and uses therefor |
US5646149A (en) | 1993-12-08 | 1997-07-08 | Alcon Laboratories, Inc. | Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents |
US5703071A (en) | 1990-08-29 | 1997-12-30 | Pharmacia & Upjohn Company | Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992020661A1 (en) * | 1991-05-22 | 1992-11-26 | Merck & Co., Inc. | N, n-diacylpiperazines |
KR20010013387A (en) * | 1997-06-16 | 2001-02-26 | 디르크 반테 | Use of draflazine-analogues for treating pain |
US6251919B1 (en) * | 1998-02-27 | 2001-06-26 | Warner-Lambert | Heterocyclic substituted aniline calcium channel blockers |
US6011035A (en) * | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
-
2000
- 2000-12-20 MX MXPA02006137A patent/MXPA02006137A/en unknown
- 2000-12-20 CA CA2397681A patent/CA2397681C/en not_active Expired - Fee Related
- 2000-12-20 JP JP2001547077A patent/JP2003518107A/en active Pending
- 2000-12-20 WO PCT/CA2000/001558 patent/WO2001046166A2/en active Application Filing
- 2000-12-20 AU AU24957/01A patent/AU784848B2/en not_active Ceased
- 2000-12-20 EP EP00988532A patent/EP1242398A2/en not_active Withdrawn
-
2002
- 2002-06-19 NO NO20022948A patent/NO326939B1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703071A (en) | 1990-08-29 | 1997-12-30 | Pharmacia & Upjohn Company | Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases |
US5428038A (en) | 1991-04-11 | 1995-06-27 | Dr. Willmar Schwabe Gmbh & Co. | Benzopyranones, a method for producing them and uses therefor |
US5646149A (en) | 1993-12-08 | 1997-07-08 | Alcon Laboratories, Inc. | Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents |
Non-Patent Citations (10)
Title |
---|
BOURINET, E. ET AL., NATURE NEUROSCIENCE, vol. 2, 1999, pages 407 - 415 |
CRIBBS, L.L. ET AL., CIRCULATION RESEARCH, vol. 83, 1998, pages 103 - 109 |
DUNLAP, K. ET AL., TRENDS NEUROSCI, vol. 18, 1995, pages 89 - 98 |
GOULD, R.J. ET AL., PROC NATL ACAD SCI USA, vol. 80, 1983, pages 5122 - 5125 |
LEE, J.H. ET AL., JOURNAL OF NEUROSCIENCE, vol. 19, 1999, pages 1912 - 1921 |
MCCLESKEY, E.W. ET AL., CURR TOPICS MEMBR, vol. 39, 1991, pages 295 - 326 |
PEREZ-REYES ET AL., NATURE, vol. 391, 1998, pages 896 - 900 |
SATHER, W.A. ET AL., NEURON, vol. 11, 1995, pages 291 - 303 |
STEA, A. ET AL., PROC NATL ACAD SCI USA, vol. 91, 1994, pages 10576 - 10580 |
STEA, A. ET AL.: "Handbook of Receptors and Channels", 1994, CRC PRESS |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10226459B2 (en) | 2003-04-24 | 2019-03-12 | Incyte Holdings Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
US8637497B2 (en) | 2003-04-24 | 2014-01-28 | Incyte Corporation | AZA spiro alkane derivatives as inhibitors of metalloproteases |
US8039471B2 (en) | 2003-04-24 | 2011-10-18 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
US9403775B2 (en) | 2003-04-24 | 2016-08-02 | Incyte Corporation | AZA spiro alkane derivatives as inhibitors of metalloproteases |
US9801877B2 (en) | 2003-04-24 | 2017-10-31 | Incyte Corporation | AZA spiro alkane derivatives as inhibitors of metalloproteases |
US7723349B2 (en) | 2003-04-24 | 2010-05-25 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US7595329B2 (en) | 2004-06-15 | 2009-09-29 | Pfizer Inc | Benzimidazolone carboxylic acid derivatives |
US7705020B2 (en) | 2004-06-15 | 2010-04-27 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
US7659395B2 (en) | 2004-08-30 | 2010-02-09 | Neuromed Pharmaceuticals Ltd. | Urea derivatives as calcium channel blockers |
US7649092B2 (en) | 2004-08-30 | 2010-01-19 | Neuromed Pharmaceuticals Ltd. | Urea derivatives as calcium channel blockers |
US7378420B2 (en) | 2004-08-30 | 2008-05-27 | Neuromed Pharmaceuticals Ltd. | Urea derivatives as calcium channel blockers |
US7511077B2 (en) | 2005-02-09 | 2009-03-31 | Neuromed Pharmaceuticals Ltd. | Diamine calcium channel blockers |
US7589109B2 (en) | 2005-02-22 | 2009-09-15 | Pfizer Inc | Oxyindole derivatives |
EP2061780A4 (en) * | 2006-09-14 | 2010-12-22 | Zalicus Pharmaceuticals Ltd | Diaryl piperidine compounds as calcium channel blockers |
EP2061780A1 (en) * | 2006-09-14 | 2009-05-27 | Neuromed Pharmaceuticals, Ltd. | Diaryl piperidine compounds as calcium channel blockers |
US9434692B2 (en) | 2006-10-03 | 2016-09-06 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US9732039B2 (en) | 2006-10-03 | 2017-08-15 | Arena Pharmeceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10351531B2 (en) | 2006-10-03 | 2019-07-16 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US7659286B2 (en) | 2006-10-20 | 2010-02-09 | Astrazeneca Ab | N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide |
US7977355B2 (en) | 2006-10-20 | 2011-07-12 | Astrazeneca Ab | N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl |
US10058549B2 (en) | 2007-08-15 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-α]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
US10059691B2 (en) | 2008-04-02 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US10787437B2 (en) | 2008-04-02 | 2020-09-29 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US9801856B2 (en) | 2008-10-28 | 2017-10-31 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US10543193B2 (en) | 2008-10-28 | 2020-01-28 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US10583122B2 (en) | 2008-10-28 | 2020-03-10 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US10071075B2 (en) | 2008-10-28 | 2018-09-11 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US10117851B2 (en) | 2008-10-28 | 2018-11-06 | Arena Pharmaceuticals, Inc. | Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto |
WO2011148888A1 (en) | 2010-05-27 | 2011-12-01 | あすか製薬株式会社 | Heterocyclic ring compound and h1 receptor antagonist |
US9365553B2 (en) | 2010-05-27 | 2016-06-14 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound and H1 receptor antagonist |
US10155733B2 (en) | 2015-04-28 | 2018-12-18 | Conopco, Inc. | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same |
US10307355B2 (en) | 2015-04-28 | 2019-06-04 | Conopco, Inc. | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same |
WO2016173817A1 (en) * | 2015-04-28 | 2016-11-03 | Unilever Plc | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US11304932B2 (en) | 2015-07-15 | 2022-04-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
Also Published As
Publication number | Publication date |
---|---|
JP2003518107A (en) | 2003-06-03 |
AU2495701A (en) | 2001-07-03 |
CA2397681C (en) | 2011-03-15 |
CA2397681A1 (en) | 2001-06-28 |
AU784848B2 (en) | 2006-07-06 |
NO20022948L (en) | 2002-08-19 |
WO2001046166A3 (en) | 2002-03-07 |
EP1242398A2 (en) | 2002-09-25 |
MXPA02006137A (en) | 2002-12-05 |
NO326939B1 (en) | 2009-03-16 |
NO20022948D0 (en) | 2002-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6492375B2 (en) | Partially saturated calcium channel blockers | |
US6387897B1 (en) | Preferentially substituted calcium channel blockers | |
US7064128B2 (en) | Preferentially substituted calcium channel blockers | |
CA2335461C (en) | Calcium channel blockers | |
US6310059B1 (en) | Fused ring calcium channel blockers | |
CA2397681C (en) | Partially saturated calcium channel blockers | |
US20040147529A1 (en) | Preferentially substituted calcium channel blockers | |
US20030199523A1 (en) | Heterocyclic calcium in channel blockers | |
IL150117A (en) | Substituted piperazine and piperidine calcium channel blockers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA IL JP MX NO SG |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA IL JP MX NO SG |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2397681 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 547077 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/006137 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000988532 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 24957/01 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2000988532 Country of ref document: EP |